Matthew Adamson, MD, PHD in Colorado Springs, CO - Student in an Organized Health Care Education/Training Program

Matthew Adamson, MD, PHD is a Student In An Organized Health Care Education/training Program physician based in Colorado Springs, Colorado. Matthew Adamson is licensed to practice in * (Not Available) (license number ) and his current practice location is 3805 Manchester St, Colorado Springs, Colorado. He can be reached at his office (for appointments etc.) via phone at (217) 621-3034.

NPI number for Matthew Adamson is 1033859087 and his current mailing address is 3805 Manchester St, Colorado Springs, Colorado. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1033859087.

Contact Information

	Matthew Adamson, MD, PHD
	3805 Manchester St, Colorado Springs, CO 80907-4828
	(217) 621-3034
	Not Available

Physician's Profile

Full Name	Matthew Adamson
Gender	Male
Speciality	Student In An Organized Health Care Education/training Program
Location	3805 Manchester St, Colorado Springs, Colorado
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1033859087
Provider Enumeration Date: 03/29/2022
Last Update Date: 03/29/2022

Medical Identifiers

Medical identifiers for Matthew Adamson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1033859087	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2084P0800X	Psychiatry & Neurology - Psychiatry	1234 (Colorado)	Secondary
390200000X	Student In An Organized Health Care Education/training Program	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Matthew Adamson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Matthew Adamson, MD, PHD 3805 Manchester St, Colorado Springs, CO 80907-4828 Ph: (217) 621-3034	Matthew Adamson, MD, PHD 3805 Manchester St, Colorado Springs, CO 80907-4828 Ph: (217) 621-3034

News Archive

Dana-Farber doctor hosts live program on Twitter to discuss head and neck cancers

The recent news that Michael Douglas has been diagnosed with stage 4 throat cancer has raised public awareness of head and neck cancer. What causes throat cancer and what are the symptoms? Are there ways to prevent or reduce the risk of throat cancer? How is the human papillomavirus (HPV) related to oral cancer?

New sculpture to commemorate Sir Frederick Banting

One of the greatest gifts Canada has given the world will be celebrated this Sunday at Banting House National Historic Site of Canada located in London, Ont. with the unveiling of a three-metre high sculpture to commemorate the birth of Sir Frederick Banting's brilliant idea that led to the discovery of insulin. Banting House National Historic Site of Canada is a public site dedicated to the historic significance of Sir Frederick Banting.

ACSF releases report on EPA's new pollution controls for electric power plants

The American Clean Skies Foundation (ACSF) released a new report today on the plans of the Environmental Protection Agency (EPA) to adopt stricter pollution controls for electric power plants. The report concludes that the EPA's proposed actions are likely to spur major changes in the fuels used by the utility sector - with greater reliance on cleaner sources such as natural gas and renewable energy - and should not present reliability concerns.

Contraceptive gap in developed world

Analysis of survey data from 55 developing countries has shown that, although the use of contraception is increasing, its use by the poorest people remains low. A 'contraceptive gap' separates the very poor from the rest of society.

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

Matthew Adamson, MD, PHD - Student in an Organized Health Care Education/Training Program in Colorado Springs, CO